drugset / Trial / NCT03543358
A Long-Term Study of Rovalpituzumab Tesirine
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this long-term, extension study is to provide ongoing safety and efficacy follow-up of subjects who participated in a rovalpituzumab tesirine study that has completed the primary analysis and that is closing.
Timeline
- Start
- 2018-09-10
- Primary completion
- 2019-11-26
- Completion
- 2019-11-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rovalpituzumab tesirine | Other / unclassified | 0.3 mg/kg | Intravenous |